Noema Pharma raises CHF 54 million in Series A financing round

Please login or
register
01.12.2020
symbolic picture lab

Sofinnova Partners and Polaris Partners have co-led an oversubscribed CHF 54 million series A round for Noema Pharma, a Swiss clinical-stage company targeting orphan neurological disorders that successfully licensed four clinical-stage product-candidates from Roche.

In 2019, Noema Pharma obtained a seed investment from Sofinnova Partners, a leading European life sciences, venture capital firm based in Paris, London and Milan to embark on a new journey to address orphan neurological disorders characterized by imbalanced neuronal networks. Noema leverages the latest scientific discoveries in neuroscience to identify and pursue promising new indications and to elaborate a strategy around four mid-clinical-stage therapeutic product candidates that it licensed from Roche.

Lead product NOE-101 is Phase 2b-ready for two indications: persistent seizures in Tuberous Sclerosis Complex (TSC) and severe pain in Trigeminal Neuralgia (TN) while NOE-105 is in preparation for Phase 2b testing to treat Tourette Syndrome. The company is undertaking validation studies in undisclosed indications for two additional clinical-stage assets. The product candidates will be developed in neurological indications with severe unmet need, such as seizures in tuberculosis sclerosis complex (TSC), trigeminal neuralgia, Tourette syndrome and other rare neurological disorders.

Inlicensed product candidates from Roche

Today, the Basel-based company announced the closing of an oversubscribed series A round co-led by Sofinnova Partners and Polaris Partners with the participation of a global consortium of new international investors including Gilde Healthcare, Invus and BioMed Partners. The pharma giant, Roche, received a shareholding in Noema in exchange for rights to four clinical-stage product candidates.

Luigi Costa, CEO of Noema, said, “The successful licensing of four clinical-stage product-candidates from Roche and our up-sized CHF54 million Series A financing, will enable Noema to reach value-creating development milestones with all four products. We are now in a solid position to continue advancing these potentially life-changing therapeutics for patients who have no satisfactory treatment options.

New board members
In line with the new financing round, Noema has welcomed two members to its Board of Directors. Darren Carroll, Partner at Polaris Partners and Arthur Franken, General Partner at Gilde Healthcare, will join Antoine Papiernik of Sofinnova Partners.

“Noema is a prime example of the exceptional pharma-grade assets Europe has to offer, along with a flourishing talent pool. We are delighted to co-lead this round of global investors and look forward to working with Noema to make this a global success,said Caroll.

(Press release/RAN)

0Comments

More news about

Noema Pharma AG

Company profiles on startup.ch

Noema Pharma AG

rss